Why it may matterVerify against the original reporting
The cash-out at $31.50 per share replaces public equity value for CPRX holders; if CPRX traded above $31.50 pre-announcement, the deal creates an immediate negative price adjustment for current shareholders. Delisting removes any possibility of upside from catalysts prior to completion; historical analogs include cash-out mergers where trading adjacencies compress to the offer price.
AI summary
What happened, with direct paths to the underlying reporting
Angelini Pharma completes the Catalyst Pharmaceuticals acquisition, folding Catalyst’s brain-health portfolio into Angelini’s platform with Blackstone and CDP Equity financing. Catalyst shareholders receive $31.50 per share, valuing the deal at about $4.1B and Catalyst stock is delisted. The transaction accelerates Angelini’s U.S. expansion and global leadership in brain health and rare diseases.
Angelini Pharma completes Catalyst acquisition, CPRX to join Angelini Brain Health platform.
Blackstone to invest €1B in preferred equity; CDP Equity to buy 23.5% Angelini stake.
Cash per Catalyst share: $31.50; equity value ~USD 4.1B; Catalyst delisted.
BNP Paribas-led financing; Morgan Stanley and Centerview Partners as advisors.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals, delivering $31.50 in cash per Catalyst share and resulting in CPRX being delisted. The deal is financed…
Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share, totaling around $4.1 billion. This transaction strengthens Angelini's position in the U.S. mar…
- CPRX reported adjusted earnings of 38 cents per share, surpassing estimates. - Total revenues were $98.5 million, driven by product sales including Firdapse and Fycompa. - Year…
